Open AccessIn Reply
Author(s) -
Auchus Richard J.,
Yu Margaret K.,
Nguyen Suzanne,
Mundle Suneel D.
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0010
Subject(s) - medicine , abiraterone acetate , prostate cancer , prednisone , food and drug administration , abiraterone , dexamethasone , oncology , pharmacology , cancer , androgen deprivation therapy , androgen receptor
Dexamethasone combined with abiraterone acetate might result in improved survival in the treatment of castration‐resistant prostate cancer compared with the Food and Drug Administration‐approved prednisone combination, but the hypothesis must be confirmed with with clinical studies comparing the two combinations.